ChiCTR2400079460 版本V1.0 版本创建时间2024/01/03 17:33:46 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2400079460 

最近更新日期:

Date of Last Refreshed on:

2024-01-03 17:33:00 

注册时间:

Date of Registration:

2024-01-03 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

慢性疼痛微创介入治疗相关疼痛现状及危险因素分析:一项横断面临床研究

Public title:

Pain status and its risk factors associated with minimally invasive interventional therapy for chronic pain: a cross-sectional clinical study

注册题目简写:

English Acronym:

研究课题的正式科学名称:

慢性疼痛微创介入治疗相关疼痛现状及危险因素分析:一项横断面临床研究

Scientific title:

Pain status and its risk factors associated with minimally invasive interventional therapy for chronic pain: a cross-sectional clinical study

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

王然 

研究负责人:

徐晨婕 

Applicant:

Wang Ran 

Study leader:

Xu Chenjie 

申请注册联系人电话:

Applicant telephone:

+86 139 1204 3223

研究负责人电话:

Study leader's telephone:

+86 139 5180 9998

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

13912043223@163.com

研究负责人电子邮件:

Study leader's E-mail:

xcj2001@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

江苏省南京市秦淮区长乐路68号

研究负责人通讯地址:

江苏省南京市秦淮区长乐路68号

Applicant address:

68 Changle Road, Qinhuai District, Nanjing, Jiangsu

Study leader's address:

68 Changle Road, Qinhuai District, Nanjing, Jiangsu

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

南京医科大学附属南京医院(南京市第一医院)

Applicant's institution:

Nanjing First Hospital, Nanjing Medical University

研究负责人所在单位:

南京医科大学附属南京医院(南京市第一医院)

Affiliation of the Leader:

Nanjing First Hospital, Nanjing Medical University

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

KY20231109-07

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

南京市第一医院伦理委员会

Name of the ethic committee:

Ethics Committee of Nanjing First Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2023-11-09 00:00:00

伦理委员会联系人:

张英

Contact Name of the ethic committee:

Zhang Ying

伦理委员会联系地址:

南京医科大学附属南京医院(南京市第一医院)

Contact Address of the ethic committee:

Nanjing First Hospital, Nanjing Medical University

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 25 5227 1064

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

南京医科大学附属南京医院(南京市第一医院)

Primary sponsor:

Nanjing First Hospital, Nanjing Medical University

研究实施负责(组长)单位地址:

江苏省南京市秦淮区长乐路68号

Primary sponsor's address:

68 Changle Road, Qinhuai District, Nanjing, Jiangsu

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏

市(区县):

Country:

China

Province:

Jiangsu

City:

单位(医院):

南京医科大学附属南京医院(南京市第一医院)

具体地址:

江苏省南京市秦淮区长乐路68号

Institution
hospital:

Nanjing First Hospital, Nanjing Medical University

Address:

68 Changle Road, Qinhuai District, Nanjing, Jiangsu

经费或物资来源:

Source(s) of funding:

None

Target disease:

Pain

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

横断面 

Study design:

Cross-sectional 

研究目的:

1. 主要目的:调查目前临床上慢性疼痛微创治疗相关疼痛的现状,了解中重度治疗相关疼痛发生情况,以及与其发生相关的危险因素。 2. 次要目的:调查中重度治疗相关疼痛的发生与治疗舒适度、治疗完成情况的相关性。  

Objectives of Study:

1. Main objective: To investigate the current clinical status of pain related to minimally invasive treatment for chronic pain, and to understand the occurrence of moderate to severe treatment-related pain and its associated risk factors. 2. Secondary objective: To investigate the correlation between the occurrence of moderate to severe treatment-related pain and the comfort level and completion of treatment.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

(1)疼痛科住院的慢性疼痛患者,病程>3月; (2)拟接受微创介入治疗:包括关节穿刺注射治疗、肌肉骨骼穿刺注射治疗、神经阻滞治疗; (3)患者愿意接受本次调查研究。

Inclusion criteria

(1) The duration of chronic pain patients admitted to the pain department was >3 months; (2) Minimally invasive interventional therapy: including joint injection therapy, musculoskeletal injection therapy, nerve block therapy; (3) The patient is willing to accept this investigation.

排除标准:

(1)年龄<18岁; (2)认知功能障碍等因素无法配合调查研究; (3)同次治疗不同部位;

Exclusion criteria:

(1) Age <18 years old; (2) Cognitive dysfunction and other factors can not cooperate with the investigation and research; (3) Treating different parts of body at the same time;

研究实施时间:

Study execute time:

From 2024-02-01 00:00:00 To 2026-01-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-02-01 00:00:00 To 2025-10-31 00:00:00  

干预措施:

Interventions:

组别:

观察组

样本量:

468

Group:

Observation group

Sample size:

干预措施:

干预措施代码:

Intervention:

NA

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

江苏 

市(区县):

 

Country:

China 

Province:

Jiangsu 

City:

 

单位(医院):

南京医科大学附属南京医院(南京市第一医院) 

单位级别:

三甲 

Institution
hospital:

Nanjing First Hospital, Nanjing Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

疼痛数字评分

指标类型:

主要指标

Outcome:

NRS

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

疼痛干扰睡眠评分

指标类型:

次要指标

Outcome:

SIS

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

治疗完成情况

指标类型:

次要指标

Outcome:

Treatment completion

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

再次接受治疗意愿

指标类型:

次要指标

Outcome:

Willingness to receive treatment again

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age None years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

试验结束后2年,通过发表期刊文章公开原始数据

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Share by publication 2 years after the end of the trial

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据通过CRF表格记录,并由研究人员负责管理

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The primary data were collected on Case-Report Form(CRF), which will be saved and managed by searcher

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2024-01-03 17:33:00